Zhao Meng-Yu, Shen Zhao-Lei, Dai Hongzhen, Xu Wan-Yan, Wang Li-Na, Gu Yu-, Zhao Jie-Hui, Yu Tian-Hang, Wang Cun-Zhi, Xu Jia-Feng, Chen Guan-Jun, Chen Dong-Hui, Hong Wen-Ming, Zhang Fang
Department of Neurosurgery, First Affiliated Hospital of Anhui Medical University, Hefei, China.
School of Nursing, Anhui Medical University, Hefei, China.
Front Immunol. 2025 Feb 5;16:1512867. doi: 10.3389/fimmu.2025.1512867. eCollection 2025.
Personalized precision medicine (PPPM) in cancer immunology and oncology is a rapidly advancing field with significant potential. Gliomas, known for their poor prognosis, rank among the most lethal brain tumors. Despite advancements, there remains a critical need for precise, individualized treatment strategies.
We conducted a comprehensive analysis of RNA-seq and microarray data from the TCGA and GEO databases, supplemented by single-cell RNA sequencing (scRNA-seq) data from glioma patients. By integrating single-cell sequencing analysis with foundational experiments, we investigated the molecular variations and cellular interactions within neural glioma cell subpopulations during tumor progression.
Our single-cell sequencing analysis revealed distinct gene expression patterns across glioma cell subpopulations. Notably, differentiation trajectory analysis identified NUSAP1 as a key marker for the terminal subpopulation. We found that elevated NUSAP1 expression correlated with poor prognosis, prompting further investigation of its functional role through both cellular and animal studies.
NUSAP1-based risk models hold potential as predictive and therapeutic tools for personalized glioma treatment. In-depth exploration of NUSAP1's mechanisms in glioblastoma could enhance our understanding of its response to immunotherapy, suggesting that targeting NUSAP1 may offer therapeutic benefits for glioma patients.
癌症免疫学和肿瘤学中的个性化精准医学（PPPM）是一个快速发展且具有巨大潜力的领域。胶质瘤以其预后差而闻名，是最致命的脑肿瘤之一。尽管取得了进展，但仍迫切需要精确的个体化治疗策略。
我们对来自TCGA和GEO数据库的RNA测序（RNA-seq）和微阵列数据进行了全面分析，并辅以胶质瘤患者的单细胞RNA测序（scRNA-seq）数据。通过将单细胞测序分析与基础实验相结合，我们研究了神经胶质瘤细胞亚群在肿瘤进展过程中的分子变异和细胞间相互作用。
我们的单细胞测序分析揭示了胶质瘤细胞亚群之间不同的基因表达模式。值得注意的是，分化轨迹分析确定NUSAP1是终末亚群的关键标志物。我们发现NUSAP1表达升高与预后不良相关，这促使我们通过细胞和动物研究进一步探究其功能作用。
基于NUSAP1的风险模型有望成为胶质瘤个性化治疗的预测和治疗工具。深入探索NUSAP1在胶质母细胞瘤中的作用机制可能会增进我们对其免疫治疗反应的理解，这表明靶向NUSAP1可能为胶质瘤患者带来治疗益处。
